Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.
about
Agent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivityAn open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.The future of physiologically based pharmacokinetic modeling to predict drug exposure in pregnant women.Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and InfantsDelineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.PBPK as a tool in regulatory review.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Oral anticoagulants in older adults with atrial fibrillation.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.Dealing with the complex drug-drug interactions: towards mechanistic models.Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities.Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions.From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example.A proposal for scientific framework enabling specific population drug dosing recommendations.Physiologically based and population PK modeling in optimizing drug development: A predict-learn-confirm analysis.Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling.Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
P2860
Q27028010-24C86F45-5EA0-4073-BA52-4D292F5892B1Q34559413-5523FB32-4D24-4A5B-BADD-FB07E1F66EB8Q35079761-30065D69-541D-4B61-BA38-01366451718BQ36737498-7E635061-F5AE-4EBA-BC8E-C1C2948F9772Q36910606-8F51B61C-BBDE-4328-A7DA-B2326DF4EB83Q37208505-11F87BD9-3E85-4481-9CC5-35D3ECBAC068Q37726177-3EC4E3EB-5C34-48CF-AAD6-6C3E4F6467A2Q37986722-6BDC140D-ADFE-45BF-BD0E-B0773970E2E6Q38014312-EF915D0E-B593-48E1-9435-7D9AE19E03A6Q38076076-9289937E-1EB8-462E-BEA0-1DF9E06FD124Q38087695-5FBF54E9-EBFC-410D-B148-6DCB1E0A6391Q38287050-3721637C-4664-4372-9D9F-5B9F749B5B28Q38302225-07867238-AA57-49B7-BD84-BA14E4A2BF01Q38351385-C67AEAD6-EF67-47A7-9585-DEF0E92E02DAQ38527434-1DB1BD98-2B82-4CE5-B7B5-ACF604009D9BQ38699135-04C15C1A-8E07-48AD-A5CC-B2AEE72C85CAQ38844656-B18F7470-B97C-48FC-ABDA-DE9693BE5F83Q38928302-837F2212-24DD-4733-8696-0871DC923860Q38959281-A7A6294E-AAFD-4A30-B1A2-FBC51F7D1D2BQ39032909-D6B45390-2A8E-46C2-8F90-1D77EC666BF7Q39240124-9D2FB358-0142-4824-B3BC-DCA59CB1ADFFQ39645850-A8268D37-4D11-460B-BFD1-7DBF97F4E1A3Q40799708-1315469A-C8BC-4E00-A7E9-83999FA1ADD2Q40882268-70D3EEC5-43A4-406B-8A34-C61531CFF69AQ41850697-3B781972-E6B3-4B39-AEEF-C30DAFA09FE7Q47313037-F32B05FD-7998-4F84-9F3C-78D457B867CDQ47592224-6FAE7828-C1E7-45F4-9E18-5B71F04FF9A2Q53630136-2953134B-58B6-45ED-B1AB-F18176744CDEQ58073610-5B25FA7E-7A16-4B8E-98E4-BABD2A93755F
P2860
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Utility of a physiologically-b ...... cations for clinical practice.
@en
Utility of a physiologically-based pharmacokinetic
@nl
type
label
Utility of a physiologically-b ...... cations for clinical practice.
@en
Utility of a physiologically-based pharmacokinetic
@nl
prefLabel
Utility of a physiologically-b ...... cations for clinical practice.
@en
Utility of a physiologically-based pharmacokinetic
@nl
P2093
P2860
P356
P1476
Utility of a physiologically-b ...... ications for clinical practice
@en
P2093
Atiqur Rahman
Brian P Booth
Eva Gil Berglund
Joseph A Grillo
Julie Bullock
Kathy Robie-Suh
Lawrence J Lesko
P2860
P304
P356
10.1002/BDD.1771
P50
P577
2012-03-04T00:00:00Z